For research use only. Not for therapeutic Use.
Indibulin（Cat No.:I007312）is an experimental anti-cancer drug that disrupts microtubule dynamics by binding to tubulin, a key protein involved in cell division. Unlike conventional tubulin inhibitors like taxanes and vinca alkaloids, Indibulin binds to a different site on tubulin, avoiding common drug resistance mechanisms. It selectively inhibits cancer cell proliferation by preventing proper mitotic spindle formation, leading to cell cycle arrest and apoptosis. Indibulin has demonstrated efficacy in preclinical and early clinical studies against various cancers, including breast and prostate cancers, with fewer neurotoxic side effects compared to traditional tubulin-targeting agents.
| Catalog Number | I007312 |
| CAS Number | 204205-90-3 |
| Synonyms | ZIO-301；ZERO/005632；ZINC01996564；d-24851; D-24851；NCGC00160428-01.;2-(1-(4-chlorobenzyl)-1H-indol-3-yl)-2-oxo-N-(pyridin-4-yl)acetamide |
| Molecular Formula | C22H16ClN3O2 |
| Purity | ≥95% |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°C for short term , or -20°C for long term. |
| IUPAC Name | 2-[1-[(4-chlorophenyl)methyl]indol-3-yl]-2-oxo-N-pyridin-4-ylacetamide |
| InChI | InChI=1S/C22H16ClN3O2/c23-16-7-5-15(6-8-16)13-26-14-19(18-3-1-2-4-20(18)26)21(27)22(28)25-17-9-11-24-12-10-17/h1-12,14H,13H2,(H,24,25,28) |
| InChIKey | SOLIIYNRSAWTSQ-UHFFFAOYSA-N |
| SMILES | C1=CC=C2C(=C1)C(=CN2CC3=CC=C(C=C3)Cl)C(=O)C(=O)NC4=CC=NC=C4 |
| Reference | </br>1:Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors. Oostendorp RL, Witteveen PO, Schwartz B, Vainchtein LD, Schot M, Nol A, Rosing H, Beijnen JH, Voest EE, Schellens JH.Invest New Drugs. 2010 Apr;28(2):163-70. doi: 10.1007/s10637-009-9244-6. Epub 2009 Apr 30. PMID: 19404582 </br>2:Indibulin, a novel microtubule inhibitor, discriminates between mature neuronal and nonneuronal tubulin. Wienecke A, Bacher G.Cancer Res. 2009 Jan 1;69(1):171-7. doi: 10.1158/0008-5472.CAN-08-1342. PMID: 19118000 Free Article</br>3:Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors. Kuppens IE, Witteveen PO, Schot M, Schuessler VM, Daehling A, Beijnen JH, Voest EE, Schellens JH.Invest New Drugs. 2007 Jun;25(3):227-35. Epub 2006 Dec 5. PMID: 17146730 |
